Karen Samaan
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Inflammatory Bowel Disease, Microscopic Colitis, Migraine and Headache Studies, Liver Diseases and Immunity, Celiac Disease Research and Management
Most-Cited Works
- → Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies(2019)54 cited
- → Malnutrition in the ICU Patient Population(2014)54 cited
- → Seizure Prophylaxis in Neurocritical Care: A Review of Evidence‐Based Support(2013)51 cited
- → Practice Tips and Tools for the Successful Use of U-500 Regular Human Insulin(2013)24 cited
- → Addressing safety concerns about U-500 insulin in a hospital setting(2010)18 cited
- → Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review(2020)16 cited
- → Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis(2021)12 cited
- → A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene‐related peptide ligand (galcanezumab) or receptor (erenumab) antagonist(2022)12 cited
- → OP14 Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately to severely active Ulcerative Colitis(2024)5 cited
- → P469 Effect of mirikizumab on clinical and endoscopic outcomes based on prior advanced therapy failure in patients with moderately to severely active ulcerative colitis(2023)2 cited